303 related articles for article (PubMed ID: 33204117)
1. Switch from IL-5 to IL-5-Receptor α Antibody Treatment in Severe Eosinophilic Asthma.
Drick N; Milger K; Seeliger B; Fuge J; Korn S; Buhl R; Schuhmann M; Herth F; Kendziora B; Behr J; Kneidinger N; Bergmann KC; Taube C; Welte T; Suhling H
J Asthma Allergy; 2020; 13():605-614. PubMed ID: 33204117
[TBL] [Abstract][Full Text] [Related]
2. Real-World Multicenter Experience with Mepolizumab and Benralizumab in the Treatment of Uncontrolled Severe Eosinophilic Asthma Over 12 Months.
Kayser MZ; Drick N; Milger K; Fuge J; Kneidinger N; Korn S; Buhl R; Behr J; Welte T; Suhling H
J Asthma Allergy; 2021; 14():863-871. PubMed ID: 34285513
[TBL] [Abstract][Full Text] [Related]
3. Anti-IL-5 and anti-IL-5R biologics for severe asthma. Are there any differences in their effects?
Granda P; Villamañán E; Carpio C; Laorden D; Quirce S; Álvarez-Sala R;
J Asthma; 2024 Jan; ():1-10. PubMed ID: 38266131
[TBL] [Abstract][Full Text] [Related]
4. Overall Response to Anti-IL-5/Anti-IL5-Rα Treatment in Severe Asthma Does Not Depend on Initial Bronchodilator Responsiveness.
Mümmler C; Suhling H; Walter J; Kneidinger N; Buhl R; Kayser MZ; Drick N; Behr J; Welte T; Korn S; Milger K
J Allergy Clin Immunol Pract; 2022 Dec; 10(12):3174-3183. PubMed ID: 35870725
[TBL] [Abstract][Full Text] [Related]
5. Anti-IL-5 therapies for chronic obstructive pulmonary disease.
Donovan T; Milan SJ; Wang R; Banchoff E; Bradley P; Crossingham I
Cochrane Database Syst Rev; 2020 Dec; 12(12):CD013432. PubMed ID: 33295032
[TBL] [Abstract][Full Text] [Related]
6. Real-world study in severe eosinophilic asthma patients refractory to anti-IL5 biological agents treated with benralizumab in Spain (ORBE study).
Martínez-Moragón E; García-Moguel I; Nuevo J; Resler G;
BMC Pulm Med; 2021 Dec; 21(1):417. PubMed ID: 34922515
[TBL] [Abstract][Full Text] [Related]
7. Real-life effectiveness of mepolizumab in patients with severe refractory eosinophilic asthma and multiple comorbidities.
Crimi C; Campisi R; Cacopardo G; Intravaia R; Nolasco S; Porto M; Pelaia C; Crimi N
World Allergy Organ J; 2020 Sep; 13(9):100462. PubMed ID: 32994855
[TBL] [Abstract][Full Text] [Related]
8. ChAracterization of ItaliaN severe uncontrolled Asthmatic patieNts Key features when receiving Benralizumab in a real-life setting: the observational rEtrospective ANANKE study.
Menzella F; Bargagli E; Aliani M; Bracciale P; Brussino L; Caiaffa MF; Caruso C; Centanni S; D'Amato M; Del Giacco S; De Michele F; Di Marco F; Pastorello EA; Pelaia G; Rogliani P; Romagnoli M; Schino P; Senna G; Vultaggio A; Simoni L; Ori A; Boarino S; Vitiello G; Altieri E; Canonica GW
Respir Res; 2022 Feb; 23(1):36. PubMed ID: 35183167
[TBL] [Abstract][Full Text] [Related]
9. Efficacy of benralizumab for patients with severe eosinophilic asthma: a retrospective, real-life study.
Numata T; Miyagawa H; Nishioka S; Okuda K; Utsumi H; Hashimoto M; Minagawa S; Ishikawa T; Hara H; Araya J; Kuwano K
BMC Pulm Med; 2020 Aug; 20(1):207. PubMed ID: 32746787
[TBL] [Abstract][Full Text] [Related]
10. Monoclonal Antibodies Targeting IL-5 or IL-5Rα in Eosinophilic Chronic Obstructive Pulmonary Disease: A Systematic Review and Meta-Analysis.
Zhang C; Wang Y; Zhang M; Su X; Lei T; Yu H; Liu J
Front Pharmacol; 2021; 12():754268. PubMed ID: 34795588
[No Abstract] [Full Text] [Related]
11. Targeting the IL-5 pathway in eosinophilic asthma: a comparison of mepolizumab to benralizumab in the reduction of peripheral eosinophil counts.
Ghassemian A; Park JJ; Tsoulis MW; Kim H
Allergy Asthma Clin Immunol; 2021 Jan; 17(1):3. PubMed ID: 33407869
[TBL] [Abstract][Full Text] [Related]
12. A case of bullous pemphigoid developing under treatment with benralizumab for bronchial asthma.
Tanaka A; Fujimura Y; Fuke S; Izumi K; Ujiie H
J Dermatol; 2023 Sep; 50(9):1199-1202. PubMed ID: 37122191
[TBL] [Abstract][Full Text] [Related]
13. Treatment with interleukin (IL)-5/IL-5 receptor antibodies in patients with severe eosinophilic asthma and COPD.
Drick N; Fuge J; Seeliger B; Speth M; Vogel-Claussen J; Welte T; Suhling H
ERJ Open Res; 2022 Oct; 8(4):. PubMed ID: 36299360
[TBL] [Abstract][Full Text] [Related]
14. Oral corticosteroid sparing effects of anti-IL5/ anti-IL5 receptor treatment after 2 years of treatment.
Bjerrum AS; Skjold T; Schmid JM
Respir Med; 2021 Jan; 176():106260. PubMed ID: 33264712
[TBL] [Abstract][Full Text] [Related]
15. Effectiveness of mepolizumab therapy in patients with severe eosinophilic asthma: Austrian real-life data.
Renner A; Marth K; Patocka K; Idzko M; Pohl W
Pulm Pharmacol Ther; 2020 Oct; 64():101946. PubMed ID: 32949705
[TBL] [Abstract][Full Text] [Related]
16. Engineering bispecific T-cell engagers to deplete eosinophils for the treatment of severe eosinophilic asthma.
Kim JH; Kim DS; Park HS; Kim YS
Clin Immunol; 2023 Oct; 255():109755. PubMed ID: 37673224
[TBL] [Abstract][Full Text] [Related]
17. Engineering of Humanized Antibodies Against Human Interleukin 5 Receptor Alpha Subunit That Cause Potent Antibody-Dependent Cell-Mediated Cytotoxicity.
Kim JE; Lee DH; Jung K; Kim EJ; Choi Y; Park HS; Kim YS
Front Immunol; 2020; 11():593748. PubMed ID: 33488590
[TBL] [Abstract][Full Text] [Related]
18. Asthma Control in Patients with Severe Eosinophilic Asthma Treated with Reslizumab: Spanish Real-Life Data.
Pérez de Llano LA; Cosío BG; Lobato Astiárraga I; Soto Campos G; Tejedor Alonso MÁ; Marina Malanda N; Padilla Galo A; Urrutia Landa I; Michel de la Rosa FJ; García-Moguel I;
J Asthma Allergy; 2022; 15():79-88. PubMed ID: 35058696
[TBL] [Abstract][Full Text] [Related]
19. Significant improvement in lung function and asthma control after benralizumab treatment for severe refractory eosinophilic asthma.
Menzella F; Ruggiero P; Galeone C; Scelfo C; Bagnasco D; Facciolongo N
Pulm Pharmacol Ther; 2020 Oct; 64():101966. PubMed ID: 33039666
[TBL] [Abstract][Full Text] [Related]
20. Antibodies targeting the interleukin-5 signaling pathway used as add-on therapy for patients with severe eosinophilic asthma: a review of the mechanism of action, efficacy, and safety of the subcutaneously administered agents, mepolizumab and benralizumab.
Hillas G; Fouka E; Papaioannou AI
Expert Rev Respir Med; 2020 Apr; 14(4):353-365. PubMed ID: 31958239
[No Abstract] [Full Text] [Related]
[Next] [New Search]
